Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of September 2025, specifically detailing share repurchases executed on September 5, 2025. The announcement was made on September 8, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, or cash flow) for a reporting period.
- Shares Purchased (Sept 5, 2025): 276,710 ordinary shares.
- Price Range: Lowest price paid was 1,463.00 GBp; highest price paid was 1,477.50 GBp.
- Volume-Weighted Average Price (VWAP): 1,472.87 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON). No purchases were made on CBOE (CHIX or BATE).
- Broker: Merrill Lynch International.
Material Changes and Cumulative Activity
This transaction is part of an existing buyback programme initiated via a non-discretionary agreement on June 4, 2025.
- Cumulative Purchases (Since June 4, 2025): 27,592,177 ordinary shares.
- Treasury Shares Held: 245,726,560 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,069,675,167 ordinary shares.
- Total Voting Rights: 4,069,675,167.
- Treasury Voting Rights Percentage: 6.04% (in accordance with DTR 5.5.1R).
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the company's Annual Report on Form 20-F for 2024 and Q2 Results for 2025. No new specific guidance or outlook was provided in this specific transaction report.
Key Facts for Investor Verification
- Verify the total number of shares in issue (4,069,675,167) to calculate accurate ownership percentages under Disclosure Guidance and Transparency Rules.
- Confirm the cumulative buyback volume of 27.59 million shares since the programme's inception on June 4, 2025.
- Note that the company holds 6.04% of its own voting rights in treasury, which do not carry voting rights.
- Review the referenced Form 20-F (2024) and Q2 2025 results for detailed risk factors affecting forward-looking statements.